Groups of 3-6 patients are sequentially assigned to receive escalating doses of SU5416 in 33% increments. Study drug is administered as a twice-weekly intravenous injection for 4 weeks. In the absence of unacceptable toxicity, responding patients may continue on SU5416 in 4-week treatment cycles for a maximum of 1 year or until the presence of unacceptable toxicity or tumor progression.

Eligibility

Ages Eligible for Study:

18 Years and older

Genders Eligible for Study:

Both

Accepts Healthy Volunteers:

No

Criteria

Inclusion Criteria

You may be eligible for this study if you:

Are at least 18 years old.

Are HIV-positive.

Have KS with at least 5 skin lesions.

Have been in stable condition for at least 6 weeks prior to study entry, if receiving antiretroviral therapy.

Agree to use effective methods of birth control during the study.

Exclusion Criteria

You will not be eligible for this study if you:

Have had surgery within 4 weeks of study entry.

Have taken certain medications, including therapy for KS, within 3 weeks prior to study entry.

Have not recovered from previous cancer treatment (chemotherapy, radiotherapy, or immunotherapy).

Are pregnant.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00002226